Global Plasma Protein Therapeutics Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Plasma Protein Therapeutics market size was valued at US$ 36350 million in 2024 and is forecast to a readjusted size of USD 59680 million by 2031 with a CAGR of 7.4% during review period.
Plasma Protein Therapeutics is use blood products to treat disease.Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.
The plasma protein therapeutics market is driven by the increasing prevalence of rare and chronic diseases such as hemophilia, primary immunodeficiency, and autoimmune disorders, which require life-saving plasma-derived treatments. Advances in plasma fractionation techniques and the growing demand for immunoglobulins, albumin, and clotting factors are further fueling market growth. Additionally, improvements in diagnostic technologies have led to earlier detection and treatment of these conditions, expanding the patient pool for plasma protein therapies. Increasing awareness and access to these treatments in developing regions are also contributing to market expansion.A significant challenge in the plasma protein therapeutics market is the limited availability of plasma due to the complex and time-consuming process of plasma collection and fractionation. This often results in supply shortages, which can affect patient access to essential therapies. The high cost of plasma protein therapies, due to the labor-intensive production process and stringent regulatory requirements, also poses a barrier to treatment affordability. Furthermore, the market faces increasing competition from recombinant therapies, which are being developed as alternatives to plasma-derived products, potentially impacting market share.
Takeda, CSL and Grifolsare the leaders of the Plasma Protein Therapeutics industry, The top five manufacturers held 73.28% of the market. North America is the major region of the global market, which takes about 40% market share.
This report is a detailed and comprehensive analysis for global Plasma Protein Therapeutics market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Plasma Protein Therapeutics market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Plasma Protein Therapeutics market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Plasma Protein Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Plasma Protein Therapeutics market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Plasma Protein Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Plasma Protein Therapeutics market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Plasma Protein Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Coagulation Factor
Immune Globulin
Albumin
Others
Market segment by Application
Hemophilia
PID
Others
Major players covered
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Plasma Protein Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Plasma Protein Therapeutics, with price, sales quantity, revenue, and global market share of Plasma Protein Therapeutics from 2020 to 2025.
Chapter 3, the Plasma Protein Therapeutics competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Plasma Protein Therapeutics breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Plasma Protein Therapeutics market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Plasma Protein Therapeutics.
Chapter 14 and 15, to describe Plasma Protein Therapeutics sales channel, distributors, customers, research findings and conclusion.
Plasma Protein Therapeutics is use blood products to treat disease.Human blood plasma is nature's raw material for dozens of life-saving treatments and medications. By extracting the active ingredients and disinfection, people get related preparations from blood plasma, which is called blood product.
The plasma protein therapeutics market is driven by the increasing prevalence of rare and chronic diseases such as hemophilia, primary immunodeficiency, and autoimmune disorders, which require life-saving plasma-derived treatments. Advances in plasma fractionation techniques and the growing demand for immunoglobulins, albumin, and clotting factors are further fueling market growth. Additionally, improvements in diagnostic technologies have led to earlier detection and treatment of these conditions, expanding the patient pool for plasma protein therapies. Increasing awareness and access to these treatments in developing regions are also contributing to market expansion.A significant challenge in the plasma protein therapeutics market is the limited availability of plasma due to the complex and time-consuming process of plasma collection and fractionation. This often results in supply shortages, which can affect patient access to essential therapies. The high cost of plasma protein therapies, due to the labor-intensive production process and stringent regulatory requirements, also poses a barrier to treatment affordability. Furthermore, the market faces increasing competition from recombinant therapies, which are being developed as alternatives to plasma-derived products, potentially impacting market share.
Takeda, CSL and Grifolsare the leaders of the Plasma Protein Therapeutics industry, The top five manufacturers held 73.28% of the market. North America is the major region of the global market, which takes about 40% market share.
This report is a detailed and comprehensive analysis for global Plasma Protein Therapeutics market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Plasma Protein Therapeutics market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Plasma Protein Therapeutics market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Plasma Protein Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Plasma Protein Therapeutics market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Plasma Protein Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Plasma Protein Therapeutics market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Plasma Protein Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Coagulation Factor
Immune Globulin
Albumin
Others
Market segment by Application
Hemophilia
PID
Others
Major players covered
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Plasma Protein Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Plasma Protein Therapeutics, with price, sales quantity, revenue, and global market share of Plasma Protein Therapeutics from 2020 to 2025.
Chapter 3, the Plasma Protein Therapeutics competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Plasma Protein Therapeutics breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Plasma Protein Therapeutics market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Plasma Protein Therapeutics.
Chapter 14 and 15, to describe Plasma Protein Therapeutics sales channel, distributors, customers, research findings and conclusion.
Table of Contents
137 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Plasma Protein Therapeutics by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
